What's Happening?
Dr. Susan Bullman, an associate professor of Immunology and Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, has been awarded the 2027 Mary Beth Maddox Award and Lectureship by the Texas Academy of Medicine, Engineering,
Science and Technology (TAMEST). This recognition honors her significant contributions to understanding the role of bacteria within tumors in cancer biology. Dr. Bullman's research has demonstrated that bacteria found inside tumors can actively influence cancer development, treatment response, and immune function. Her notable discoveries include showing that *Fusobacterium nucleatum*, a bacterium linked to colorectal cancer, can travel with cancer cells to metastatic sites. Her work also suggests that targeting these bacteria could reduce tumor burden in preclinical models. The award, established in 2022 in memory of Mary Beth Maddox, acknowledges innovative cancer researchers who are advancing new approaches to understanding and treating cancer.
Why It's Important?
Dr. Bullman's research is crucial for advancing cancer treatment strategies by revealing the complex interplay between the tumor microbiome and cancer progression. Her findings open new avenues for therapeutic interventions, potentially leading to more effective cancer therapies. By understanding how bacteria interact with cancer cells and the immune system, scientists can develop methods to either target bacteria that help cancer resist treatment or utilize bacteria themselves as a form of cancer therapy. This could significantly improve patient outcomes, especially for cancers where current treatments have limitations. The recognition from TAMEST underscores the growing importance of microbiome research in oncology and highlights the potential for personalized medicine approaches based on an individual's microbial profile.
What's Next?
Dr. Bullman will be formally recognized at the TAMEST 2027 Annual Conference: Frontiers of Discovery in February 2027. Following this, she will participate in a statewide lecture series at National Cancer Institute-designated cancer centers across Texas, sharing her research and insights with a broader scientific and medical community. Her team at UT MD Anderson is actively working on harnessing the tumor-homing ability of certain bacteria, like a distinct lineage of *Fusobacterium nucleatum*, to develop bacteria-based cancer therapies. This ongoing research aims to translate her discoveries into tangible new treatment options for patients, potentially leading to clinical trials and novel therapeutic approaches in the coming years.
Beyond the Headlines
The work of Dr. Bullman and her team represents a paradigm shift in cancer research, moving beyond solely focusing on cancer cells to include the microbial ecosystem within tumors. This deeper understanding of host-microbe interactions could lead to a more holistic approach to cancer treatment, integrating microbiology with traditional oncology. The development of tools like INVADEseq, a single-cell sequencing method to profile host cells and intracellular microbes simultaneously, exemplifies the innovative methodologies being employed. This research also raises ethical considerations regarding the manipulation of microbial communities for therapeutic purposes and the potential long-term effects on patient health. Ultimately, it points towards a future where personalized cancer treatment might involve not only genetic profiling but also microbial profiling.
